Akebia Therapeutics Inc (FRA:AX9)
€ 1.642 0.149 (9.98%) Market Cap: 359.71 Mil Enterprise Value: 368.91 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 43/100

Akebia Therapeutics Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 09, 2021 / 06:45PM GMT
Release Date Price: €2.46 (-1.60%)
David Neil Lebowitz
Morgan Stanley, Research Division - VP

Welcome to the 19th Annual Morgan Stanley Healthcare Conference. I'm one of the biotech analysts, David Lebowitz. Before I get going, let me read through the requisite disclosures. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.

And with that, I'm happy to have with me, for the next session, from Akebia, the CEO, John Butler, President and CEO; and the CFO, David Spellman. Clearly, a lot going on in your space these days with you and your competitors. I guess, if you could start off by just talking about the company, your overall mission and where you see the company heading.

Questions & Answers

John P. Butler
Akebia Therapeutics, Inc. - CEO, President & Director

Sure. First, David, thanks so much for the invitation. It

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot